Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Tirabrutinib |
Synonyms | |
Therapy Description |
Tirabrutinib (ONO-4059) is a selective inhibitor of BTK, which potentially induces antibody-dependent cell-mediated cytotoxicity against tumor cells and inhibits tumor growth (PMID: 27684575, PMID: 27776353, PMID: 32583848). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Tirabrutinib | ONO-GS-4059|ONO-WG-307|ONO-4059|GS 4059|GS4059 | BTK inhibitor 38 | Tirabrutinib (ONO-4059) is a selective inhibitor of BTK, which potentially induces antibody-dependent cell-mediated cytotoxicity against tumor cells and inhibits tumor growth (PMID: 27684575, PMID: 27776353, PMID: 32583848). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04947319 | Phase II | Tirabrutinib | Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study) | Recruiting | USA | 0 |
NCT02457598 | Phase I | Entospletinib + Tirabrutinib Tirabrutinib Idelalisib + Obinutuzumab + Tirabrutinib Entospletinib + Obinutuzumab + Tirabrutinib Idelalisib + Tirabrutinib | Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies | Terminated | USA | GBR | FRA | 0 |